https://www.selleckchem.com/products/nst-628.html
28 ± 1.47-9.77 ± 1.86 nM. Many of thecompounds in this study can be considered as promising AChE and CA inhibitors. Protein kinase CK2, a heterotetrameric holoenzyme composed of two catalytic chains (CK2α) attached to a homodimer of regulatory subunits (CK2β), is a target for drug development for cancer therapy. Here, we describe the tetraiodobenzimidazole derivative ARC-3140, a bisubstrate inhibitor addressing the ATP site and the substrate-binding site of CK2 with extraordinary affinity (Ki = 84 pM). In a crystal structure of ARC-3140
Like
Comment
Share
